Head-to-head · Cost-Efficiency Index
Direct Meds vs SkinnyRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Direct Meds
Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold.
Visit Direct MedsSkinnyRx
Shoppers who have already decided on a long commitment and want the term priced openly rather than hidden behind an intake — not price-first shoppers comparing on the advertised figure.
Visit SkinnyRxThe verdict
Direct Meds and SkinnyRx tie on the Cost-Efficiency Index at 71/100, so neither wins outright on the numbers. For most shoppers we'd start with Direct Meds (ranked #58, a hair above #60) — Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold. But SkinnyRx is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Direct Meds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Direct Meds | SkinnyRx |
|---|---|---|
| Cost-Efficiency Index | 71/100 | 71/100 |
| Semaglutide / mo | $249/mo (sublingual, 90-day supply billed monthly) | $349/mo month-to-month ($299 on 4 months, $249 on 6, $199 only on 12) |
| Tirzepatide / mo | $299/mo (sublingual, 90-day supply billed monthly) | $399/mo month-to-month ($349 on 4 months, $329 on 6, $299 only on 12) |
| Semaglutide / yr (modeled) | $2,988 | $4,188 |
| Tirzepatide / yr (modeled) | $3,588 | $4,788 |
| Coverage | Not disclosed | Most states |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #58 | #60 |
Direct Meds
71/100Where the value is
- Sublingual AND injection on BOTH molecules — four GLP-1 SKUs, the widest formulation range of any provider in this ranking
- Every price is published per SKU in a public shop, with no quiz, intake or email capture in front of it
- Each product page prints a per-day equivalent beside the monthly rate ($8.03/day at $249), which is unusually concrete for this category
The tradeoffs
- $249/mo sublingual is well above this ranking's ~$144 median, and the injection route is $297 — the cheapest thing here is dearer than most rows' headline price
- The only purchasable option on every product page is a 90-DAY SUPPLY billed monthly, so three months is the smallest unit sold — there is no month-to-month rate to compare against the rows beside it
Regulatory note: the FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds in September 2025. We still list and link to Direct Meds; you should know the letter is on the public record before you decide.
SkinnyRx
71/100Where the value is
- A complete four-term ladder for both molecules is published rather than gated, so the cost of not committing is knowable before signup
- Both compounded molecules are offered, with the same term structure on each
- The twelve-month rate is genuinely low for the category if a year is a commitment you were going to make anyway
The tradeoffs
- The '$199/month' it advertises everywhere is the TWELVE-MONTH rung. The rate you can stop after a month is $349 — 75% higher — and the figure appears without that term attached
- An FDA warning letter is on public record against Lean Rx, Inc. dba SkinnyRx, issued 20 February 2026. We disclose it and we do not treat it as disqualifying
Regulatory note: the FDA issued a warning letter to Lean Rx, Inc. dba SkinnyRx in February 2026. We still list and link to SkinnyRx; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.